Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2003;2003(4):CD004443.
doi: 10.1002/14651858.CD004443.

Naloxone for shock

B Boeuf, V Poirier, F Gauvin, A M Guerguerian, C Roy, C A Farrell, J Lacroix
Meta-Analysis

Naloxone for shock

B Boeuf et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: There is pre-clinical evidence, involving several animal species, suggesting that opioid peptides play a role in the physiopathology of shock (endotoxic, hypovolemic, cardiogenic, spinal, anaphylactic). Many case reports have suggested that naloxone (an opiate antagonist) might be an effective treatment for shock in humans, but others have not supported such a point of view. This controversy led us to undertake a meta-analysis of the available evidence on the efficacy of naloxone as a treatment measure of shock in humans.

Objectives: To evaluate the effectiveness and safety of naloxone in human shock and to estimate the methodological quality of the clinical trials.

Search strategy: Computerized bibliographic search up to December 2002, review of references of all papers found on the subject and contact with primary investigators of eligible studies.

Selection criteria: Randomized controlled trials evaluating naloxone in human shock, regardless of the patient's age (adult, child or neonate).

Data collection and analysis: Three independent reviewers extracted data on study design, intervention, outcome and methodological quality.

Main results: Three independent readers reviewed 80 human publications and selected six clinical trials. Overall agreement on study selection was perfect (concordance: 100%). This meta-analysis includes six studies involving 126 patients with septic, cardiogenic, hemorrhagic or spinal shock. Naloxone therapy was associated with statistically significant hemodynamic improvement (odds ratio 0.24; 95% confidence interval [95%CI] 0.09-0.68). The mean arterial pressure was significantly higher in the naloxone groups than in the placebo groups (weighted mean difference: +9.33 mmHg; 95%CI 7.07-11.59). No heterogeneity was found for this outcome. The death rate was lower in the naloxone group (odds ratio 0.59; 95%CI 0.21-1.67) but this was consistent with the play of chance. A significant heterogeneity for the latter outcome was detected (p<0.05).

Reviewer's conclusions: Naloxone improves blood pressure, especially mean arterial blood pressure. However, the clinical usefulness of naloxone to treat shock remains to be determined, and additional randomized controlled trials are needed to assess its usefulness.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Naloxone versus control, Outcome 1 Death rate.
1.2
1.2. Analysis
Comparison 1 Naloxone versus control, Outcome 2 Reduction in dose of vasoactive drug.
2.1
2.1. Analysis
Comparison 2 After treatment, Outcome 1 Mean Arterial Blood Pressure (MAP).
2.2
2.2. Analysis
Comparison 2 After treatment, Outcome 2 Systolic Blood Pressure (SBP).
2.3
2.3. Analysis
Comparison 2 After treatment, Outcome 3 Heart Rate (HR).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

DeMaria 1985 {published data only}
    1. Maria A, Craven DE, Heffernan JJ, McIntosh TK, Grindlinger GA, McCabe WR. Naloxone versus placebo in treatment of septic shock. Lancet 1985;1:1363‐5. - PubMed
Hughes 1984 {published data only}
    1. Hughes GS. Naloxone and methylprednisalone sodium succinate enhance sympathomedullary in patients with septic shock. Life Sciences 1984;35:2319‐26. - PubMed
Lu 1995 {published data only}
    1. Lu H, Xu G, Sheng Z. Clinical effects of naloxone on hemorrhagic shock. Chung Hua Wai Ko Tsa Chih 1995;33(6):355‐8. - PubMed
Montastruc 1985 {published data only}
    1. Montastruc JL, Richard J, Cathala B. Naloxone fails to reverse blood pressure in shock: A double blind study in man. Journal de Pharmacologie 1985;16(2):313‐4. - PubMed
Roberts 1988 {published data only}
    1. Roberts DE, Dobson KE, Hall KW, Light RB. Effects of prolonged naloxone infusion in septic shock. Lancet 1988;2:699‐702. - PubMed
Safani 1989 {published data only}
    1. Safani M, Blair J, Ross D, Waki R, Li C, Libby G. Prospective, controlled, randomized trial of naloxone infusion in early hyperdynamic septic shock. Critical Care Medicine 1989;17:1004‐9. - PubMed

References to studies excluded from this review

Allolio 1986 {published data only}
    1. Allolio B, Fischer H, Kalen D, Deub U, Winkelmann W. Naloxon by therapy refractory shock [Naloxon im therapierefraktären Schock]. Klinische Wochenschrift 1986;64:16.
Allolio 1987 {published data only}
    1. Allolio B, Fischer H, Kaulen U, Deus U, Winkelmann W. Naloxone in treatment of circulatory shock resistant to conventional therapy. Klinische Wochenschrift 1987;65:213‐17. - PubMed
Bone 1982 {published data only}
    1. Bone R, Jacobs E, Wilson F, Hiller F. Naloxone reversal of hypotension: A clinical study. American Review of Respiratory Disease 1982;125:93.
Bonnet 1985 {published data only}
    1. Bonnet F, Bilaine J, Lhoste F, Mankijian B, Kerdelhue B, Rapin M. Naloxone therapy of human septic shock. Critical Care Medicine 1985;13:972‐5. - PubMed
Canady 1989 {published data only}
    1. Canady J, Williams W, Thompson I, Vincent GS, Hoover E. Use of the naloxone in septic shock. Journal of the National Medical Association 1989;81:669‐73. - PMC - PubMed
Desmonts 1978 {published data only}
    1. Desmonts JM, Bohm G, Couderc E. Hemodynamic responses to low doses of naloxone after narcotic‐nitrous oxide anesthesia. Anesthesiology 1978;49:12‐6. - PubMed
Duarte 1992 {published data only}
    1. Duarte RR, Mumtaz M, Youssef N, Nayak P, Grace BW. Effects of naloxone infusion in patients with septic shock and renal failure: A limited experience. American Journal of Nephrology 1992;12:431‐6. - PubMed
Estilo 1982 {published data only}
    1. Estilo AE, Cottrell JE. Hemodynamic and catecholamine changes after administration of naloxone. Anesthesia and Analgesia 1982;61:349‐53. - PubMed
Gerad 1983 {published data only}
    1. Gerad H, Schimpff SC, Kaplan R. Naloxone for refractory hypotension in septic shock. Clinical Research 1983;31:257A.
Groeger 1983 {published data only}
    1. Groeger JS, Carlon GC, Howland WS. Naloxone in septic shock. Critical Care Medicine 1983;11:650‐4. - PubMed
Hackshaw 1990 {published data only}
    1. Hackshaw KV, Parker GA, Roberts JW. Naloxone in septic shock. Critical Care Medicine 1990;18:47‐51. - PubMed
Hughes 1983 {published data only}
    1. Hughes GS, Porter RS, Mars R, Harker CC. Naloxone and septic shock. Annals of Internal Medicine 1983;98:559. - PubMed
ILCOR 2006 {published data only}
    1. The International Liaison Committee on Resuscitation. The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support. Pediatrics 2006;117(5):e955‐977. [DOI: 10.1542/peds.2006-0206] - DOI - PubMed
Lightfoot 2000 {published data only}
    1. Lightfoot JT, Katz L, DeBate K. Naloxone decreases tolerance to hypotensive, hypovolemic stress in healthy humans. Critical Care Medicine 2000;28:684‐91. - PubMed
Martinon 1982 {published data only}
    1. Martinon JM, Franco A, Garcia JL, Fuster M, Bao A, Martinon F, Pena J. Naloxone hydrochloride in the therapy of endotoxic shock following meningococcal disease. Initial results. Anales Espanoles de Pediatria 1982;17:457‐60. - PubMed
Oldroyd 1995 {published data only}
    1. Oldroyd KG, Gray CE, Carter R, Harvey K, Borland W, Beastall G, Cobbe SM. Activation and inhibition of the endogenous opioid system in human heart failure. British Heart Journal 1995;73:41‐8. - PMC - PubMed
Peters 1981 {published data only}
    1. Peters WP, Johnson MW, Friedman PA, Mitch WE. Pressor effect of naloxone in septic shock. Lancet 1981;1:529‐32. - PubMed
Putterman 1986 {published data only}
    1. Putterman C, Halperin P, Leykin Y, Sorkine P, Geller B, Bursztein S. Early use of naloxone in shock ‐ A clinical trial. Resuscitation 1986;13:185‐90. - PubMed
Rock 1985 {published data only}
    1. Rock P, Silverman H, Pump D, Kecala Z, Smith P, Michael JR, Summer W. Efficacy and safety of naloxone in septic shock. Critical Care Medicine 1985;13:28‐33. - PubMed
Tarelkina 1989 {published data only}
    1. Tarelkina MN, Shirokov, Tsibin IN. Experience with using narcanti (naloxone) in patients with traumatic shock. Vestnik Khirurgii Imou I I Grekova 1989;143:110‐2. - PubMed
VelizPintos 1985 {published data only}
    1. Veliz Pintos RA, Torres Bedoya MA, Forero Gomez J, Olvera Hidalgo C, Orozco Veraztegui O. Clinical evaluation of the effect of the administration of naloxone in comparison with methylprednisolone in infants with septic shock. Boletin Medico Del Hospital Infantil de Mexico 1985;42:531‐40. - PubMed

Additional references

Accettelli 1982
    1. Accettelli U, Ambrosi F, Russo L, Petris U, Stagnitti F. Use of naloxone in first aid. Clinica Terapeutica 1982;102:197‐201. - PubMed
ACCP/SCCM 1992
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20:864‐74. - PubMed
Bagrov 1993
    1. Bagrov AY. Plasma beta‐endorphin levels in acute myocardial infarction. Annals of Emergency Medicine 1993;22:268‐9. - PubMed
Cabrera 1986
    1. Cabrera Sorrosal JE, Montejo Gonzalez JC, Suarez Alvarez JR, Blesa Alpica A, Ferrero Zorita J. Failure of naloxone in septic shock. Critical Care Medicine 1986;14:79‐80. - PubMed
Campos 1986
    1. Campos JM, Zueras R, Escolano F, Villar Landeira JM. Use of naloxone in the therapy of septic shock. Revista Espanola de Anestesiologia 1986;33:451‐3. - PubMed
Cattani 1982
    1. Cattani F, Grillanda G. Use of naloxone in refractory shock. Recenti Progressi in Medicina 1982;72:647‐52. - PubMed
Chalmers 1981
    1. Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 1981;2:31‐49. - PubMed
Christensen 1986
    1. Christensen MA, Gresch JJ. Use of naloxone in septic shock: A case report and review of current literature. Journal of Burn Care and Rehabilitation 1986;7:122‐6. - PubMed
Cocchi 1984
    1. Cocchi P, Silenzi M, Calabri G, Salvi G. Naloxone in fulminant meningococcemia. Pediatric Infectious Diseases 1984;3:187. - PubMed
Cohen 1983
    1. Cohen KR, Emmons KM, Goldstein MF. Naloxone treatment of toxic shock syndrome. Archives of Internal Medicine 1983;143:1072. - PubMed
Collins 1987
    1. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Statistics in Medicine 1987;6:245‐50. - PubMed
De Groot 1983
    1. Groot GH, Schalm SW, Dirksen R, Valk KC, Boks AL. Effect of naloxone on shock in a patient with fulminant hepatic failure. Netherlands Journal of Medicine 1983;26:77‐9. - PubMed
Dirksen 1980
    1. Dirksen R, Otten M H, Wood GJ, Verbaan CJ, Haalebos MM, Verdouw PV, Nijhuis GMM. Naloxone in shock. Lancet 1980;1:1360‐1.
Einarson 1985
    1. Einarson TR, McGhan WF, Bootman JL, Sabers DL. Meta‐analysis: Quantitative integration of independent research results. American Journal of Hospital Pharmacy 1985;42:1957‐64. - PubMed
Faden 1979
    1. Faden AI, Holaday JW. Opioate antagonists: A role in the treatment of hypovolemic shock. Science 1979;205:317‐8. - PubMed
Fleiss 1986
    1. Fleiss JL. Reliability of measurement. In: Fleiss JL editor(s). The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons, 1986:17‐31.
Furman 1984
    1. Furman WL, Menke JA, Barson WJ, Miller RR. Continuous naloxone infusion in two neonates with septic shock. Journal of Pediatrics 1984;105:649‐51. - PubMed
Gaudette 1986
    1. Gaudette RR, Browne BJ. Use of naloxone in septic shock. Journal of Emergency Nursing 1986;12:81‐4. - PubMed
Gullo 1983
    1. Gullo A, Romano E. Naloxone and anaphylactic shock. Lancet 1983;1:819. - PubMed
Higgins 1981
    1. Higgins TL, Sivak ED. Reversal of hypotension with naloxone. Cleveland Clinic Quarterly 1981;48:283‐8. - PubMed
Higgins 1983
    1. Higgins TL, Sivak ED, O'Neil DM, Grave JW, Foutch DG. Reversal of hypotension by continuous naloxone infusion in a ventilator dependent patient. Annals of Internal Medicine 1983;98:47‐8. - PubMed
Holaday 1978
    1. Holiday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 1978;275:450‐1. - PubMed
Hughes 1975
    1. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Research 1975;88:295‐308. - PubMed
Jessop 1998
    1. Jessop DS. ß‐endorphin in the immune system ‐ mediator of pain and stress. Lancet 1998;351:1828‐9. - PubMed
Jolivet 1984
    1. Jolivet M, Laurion M. Shock and the administration of naloxone [Le choc et l'administration de naloxone]. Union Medicale Du Canada 1984;113:783‐5. - PubMed
Kramer 1981
    1. Kramer MS, Feinstein AR. Clinical biostatistic LIV : The biostatistics of concordance. Clinical Pharmacology and Therapeutics 1981;29:111‐23. - PubMed
Lefebvre 2000
    1. Lefebvre C, Tasiemski A, Salzet M. Opioid peptides, opiated substances and immune response [Peptides opioïdes, substances opiacées et réponse immunitaire]. Médecine/Sciences 2000;16:235‐42.
Lenz 1981
    1. Lenz K, Druml W, Gassner A, Hruby K, Kleinberger G, Laggner A. Naloxone in shock. Lancet 1981;1:834. - PubMed
Leteurtre 2003
    1. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the pediatric logistic organ dysfunction (PELOD) score. A prospective multicenter study. Lancet 2003:in press. - PubMed
Mantel 1959
    1. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. Journal of the National Cancer Institute 1959;22:719‐48. - PubMed
Marshall 1995
    1. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome. Critical Care Medicine 1995;23:1638‐52. - PubMed
Parisot 1986
    1. Parisot S, Pinaud P, Marchal C. Early septic shock and the use of naloxone in premature newborn infants [Choc septique précoce et emploi de la naloxone chez le nouveau‐né prématuré]. Archives Francaises de Pediatrie 1986;43:149. - PubMed
Pollack 1996
    1. Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated Pediatric Risk of Mortility score. Critical Care Medicine 1996;24:743‐52. - PubMed
Pourriat 1981
    1. Pourriat JL, Pierrot M, Lapandry M, Cupa M. Naloxone in septic shock [La naloxone dans le choc septique]. Nouvelle Presse Medicale 1981;10:3793‐4.
Prough 1984
    1. Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology 1984;600:485‐6. - PubMed
Putterman 1987
    1. Putterman C, Halpern P. Naloxone in circulatory shock. Klinische Wochenschrift 1987;65:926. - PubMed
Safani 1985
    1. Safani M, Libby G. Naloxone therapy of septic shock. Critical Care Medicine 1985;13:875‐6. - PubMed
Siram 1984
    1. Siram S, Park SY. Naloxone in septic shock: Report of two cases. Journal of the National Medical Association 1984;76:713‐6. - PMC - PubMed
Swinburn 1982
    1. Swinburn WR, Phelan P. Response to naloxone in septic shock. Lancet 1982;1:167. - PubMed
Tarelkina 1989
    1. Tarelkina MN, Shirokov, Tsibin IN. Experience with using narcanti (naloxone) in patients with traumatic shock. Vestnik Khirurgii Imeni I I Grekova 1989;143:110‐2. - PubMed
Tiengo 1980
    1. Tiengo M. Naloxone in irreversible shock. Lancet 1980;2:690. - PubMed
Unzueta 1987
    1. Unzueta Merino MC, Bonnin O, Cabrera Ruiz JC, Villar Landeira JM. Naloxone and cardiogenic shock. Revista Espanola de Anestesiologia Y Reanimacion 1987;34:446‐9. - PubMed
Valdiviels 1984
    1. Valdivielso A, Casado Flores J, Ruiz Beltran A, Garcia Perez J, Garcia Onieva M, Hidalgo I. Naloxone and endotoxic shock: A wonder drug?. Annales Espaňoles de Pediatría 1984;20:85‐90. - PubMed
Wichman 2000
    1. Wichman MW, Zellweger R, Ayala A, Chaudry IH. Effect of naloxone on immune responses after hemorrhagic shock. Critical Care Medicine 2000;28:184‐9. - PubMed
Wright 1980
    1. Wright DJ, Phillips M, Weller MPI. Naloxone in shock. Lancet 1980;2:1361.
Xing 1990
    1. Xing R, Yi X, Guang‐Min L, Yuan‐Wen W. Naloxone for haemorrhagic fever shock?. Tropical Doctor 1990;20:72‐3. - PubMed
Yeston 1983
    1. Yeston NS, Grasberger RC, McIntosh TK. Naloxone in reversal of hypotension in septic shock. JAMA 1983;250:2287. - PubMed

References to other published versions of this review

Boeuf 1998
    1. Boeuf B, Gauvin F, Guerguerian AM, Farrell C, Lacroix J, Jenicek M. Therapy of shock with naloxone: A meta‐analysis. Critical Care Medicine 1998;26(11):1910‐6. - PubMed